Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95361

UPID:
TRI16_HUMAN

ALTERNATIVE NAMES:
E3 ubiquitin-protein ligase TRIM16; Estrogen-responsive B box protein

ALTERNATIVE UPACC:
O95361; Q6IAL8; Q7Z6I2; Q96BE8; Q96J43

BACKGROUND:
The E3 ubiquitin-protein ligase TRIM16, known for its essential role in autophagic response and ubiquitination upon endomembrane damage, plays a crucial part in cellular defense mechanisms. By regulating the p62-KEAP1-NRF2 signaling and modulating NRF2 stability through ubiquitination, TRIM16 ensures the effective degradation of protein aggresomes. Its interaction with proteins such as p62/SQSTM, ATG16L1, and LC3B/MAP1LC3B facilitates the autophagic degradation of protein aggregates, protecting cells from oxidative stress-induced death.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Tripartite motif-containing protein 16 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.